Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price targ...

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(...

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collabo...

Guggenheim analyst Vamil Divan reiterates Vera Therapeutics (NASDAQ:VERA) with a Buy and maintains $56 price target.

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $27 to ...

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the price target from $21 to...